SCHEMBL1242271

SCHEMBL1242271

FC(F)(F)Oc1ccc(C(N2CCCC2)C(F)(c2cccnc2)c2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 6/20 0.54
KCNH2 Q12809 6/20 0.54
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPY5R Q15761 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP3A5 P20815 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 1/20 0.37
NAMPT P43490 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ABL1 P00519 2/20 0.36
OPRM1 P35372 1/20 0.36
EPHX2 P34913 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243082 0.88 KCNA5 (0.72) KCNA5KCNH2NPC1RAB9ACYP3A4
SCHEMBL1242006 0.85 KCNA5 (0.73) KCNA5KCNH2CYP3A4OPRM1
SCHEMBL1240753 0.84 KCNA5 (0.60) KCNA5KCNH2CYP3A4HTT
SCHEMBL1243505 0.84 KCNA5 (0.57) KCNA5KCNH2CYP3A4CYP3A5HTT
SCHEMBL1242361 0.81 KCNA5 (0.57) KCNA5KCNH2CYP3A4CYP3A5CYP11B1
SCHEMBL1243037 0.78 KCNA5 (0.51) KCNA5KCNH2
SCHEMBL1243523 0.77 KCNA5 (0.65) KCNA5KCNH2NPY5RCYP11B1CYP11B2
SCHEMBL1242924 0.77 KCNA5 (0.52) KCNA5KCNH2CYP3A4
SCHEMBL1242388 0.77 KCNA5 (0.49) KCNA5KCNH2CYP3A4CYP3A5
SCHEMBL1240066 0.74 KCNA5 (0.75) KCNA5KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885NPC1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.